Data from Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR<sup>Y1068</sup> Phosphorylation

Abstract

<div>Abstract<p>Glioblastomas commonly (40%) exhibit epidermal growth factor receptor (<i>EGFR</i>) amplification; half of these tumors carry the <i>EGFRvIII</i> deletion variant characterized by an in-frame deletion of exons 2–7, resulting in constitutive EGFR activation. Although EGFR tyrosine kinase inhibitors had only modest effects in glioblastoma, novel therapeutic agents targeting amplified EGFR or EGFRvIII continue to be developed.</p><p>Depatuxizumab mafodotin (ABT-414) is an EGFR-targeting antibody–drug conjugate consisting of the mAb 806 and a toxic payload, monomethyl auristatin F. Because glioma cell lines and patient-derived glioma-initiating cell models expressed too little EGFR <i>in vitro</i> to be ABT-414–sensitive, we generated glioma sublines overexpressing EGFR or EGFRvIII to explore determinants of ABT-414–induced cell death.</p><p>Overexpression of EGFRvIII induces sensitization to ABT-414 more readily than overexpression of EGFR <i>in vitro</i> and <i>in vivo</i>. Exposure to ABT-414 <i>in vivo</i> eliminated EGFRvIII-expressing tumor cells, and recurrent tumors were devoid of EGFRvIII expression. There is no bystander killing of cells devoid of EGFR expression. Surprisingly, either exposure to EGF or to EGFR tyrosin kinase inhibitors reduce EGFR protein levels and are thus not strategies to promote ABT-414–induced cell killing. Furthermore, glioma cells overexpressing kinase-dead EGFR or EGFRvIII retain binding of mAb 806 and sensitivity to ABT-414, allowing to dissociate EGFR phosphorylation from the emergence of the “active” EGFR conformation required for ABT-414 binding.</p><p>The combination of EGFR-targeting antibody–drug conjugates with EGFR tyrosine kinase inhibitors carries a high risk of failure. Promoting EGFR expression rather than phosphorylation should result in glioblastoma cell sensitization to ABT-414.</p></div>